Vlad Coric Purchases 121,951 Shares of Biohaven Ltd. (NYSE:BHVN) Stock

Biohaven Ltd. (NYSE:BHVN) CEO Vlad Coric acquired 121,951 shares of Biohaven stock in a transaction on Monday, April 22nd. The stock was purchased at an average price of $41.00 per share, with a total value of $4,999,991.00. Following the transaction, the chief executive officer now directly owns 1,788,417 shares in the company, valued at approximately $73,325,097. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Biohaven Price Performance

BHVN stock opened at $38.70 on Thursday. The business has a fifty day moving average price of $51.49 and a 200 day moving average price of $41.81. Biohaven Ltd. has a fifty-two week low of $12.35 and a fifty-two week high of $62.21. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -6.84 and a beta of 1.18.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). On average, equities analysts expect that Biohaven Ltd. will post -5.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BHVN has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of Biohaven in a report on Tuesday, April 9th. HC Wainwright increased their target price on Biohaven from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, March 4th. JPMorgan Chase & Co. increased their target price on Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. TD Cowen increased their target price on Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Finally, UBS Group increased their target price on Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $52.13.

Institutional Investors Weigh In On Biohaven

Hedge funds and other institutional investors have recently made changes to their positions in the company. Thompson Davis & CO. Inc. acquired a new stake in shares of Biohaven in the 4th quarter valued at $214,000. Prevail Innovative Wealth Advisors LLC acquired a new stake in shares of Biohaven in the 4th quarter valued at $230,000. Private Advisor Group LLC acquired a new stake in shares of Biohaven in the 4th quarter valued at $231,000. Capstone Investment Advisors LLC acquired a new stake in shares of Biohaven in the 4th quarter valued at $235,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Biohaven in the 3rd quarter valued at $236,000. 88.78% of the stock is owned by institutional investors and hedge funds.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.